Skip Navigation


Brain Advance Access originally published online on February 13, 2006
Brain 2006 129(4):1050-1058; doi:10.1093/brain/awl028
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
129/4/1050    most recent
awl028v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sossi, V.
Right arrow Articles by Stoessl, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sossi, V.
Right arrow Articles by Stoessl, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2006). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications

Vesna Sossi1, Raúl de la Fuente-Fernández3, Michael Schulzer1, John Adams2 and Jon Stoessl1,2

1 University of British Columbia, 2 Pacific Parkinson's Research Centre, Vancouver, Canada and 3 Division of Neurology, Hospital Arquitecto Marcide, 15405 Ferrol (A Coruña), Spain

Correspondence to: Vesna Sossi, PhD, Pacific Parkinson's Research Centre, Room M37, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, Canada BC V6T 2B5 E-mail: vesna{at}physics.ubc.ca

Treatment-related motor complications in Parkinson's disease have been previously linked to disease-induced pre-synaptic alterations: dopaminergic denervation and changes in dopamine (DA) release patterns. The occurrence of such complications is also known to be partly dependent on the age of disease onset, occurring more frequently in patients with disease onset at a younger age. Using positron emission tomography (PET) and 4-h-long 18F-fluorodopa (FD) scans we have investigated in vivo an age dependence of disease-induced changes in DA turnover as a possible contributing factor to the age-related differences in treatment-related motor complications. We evaluated the relative changes in DA turnover (measured by its direct inverse, effective DA distribution volume—EDV) and DA synthesis and vesicular storage capacity (quantified by the plasma input uptake rate constant Ki) in Parkinson's disease patients as a function of age (n = 27, age range 38–79 years). After correcting for disease severity, a significant negative correlation was found between age and magnitude of disease-induced decrease in EDV and in Ki in the putamen (P < 0.001, P = 0.02, respectively). However, the difference between the disease-induced decrease in EDV and that in Ki also exhibited an age dependence (P < 0.001), indicating a relatively higher disease-induced increase in DA turnover (inverse of EDV) compared with the decrease in DA synthesis and storage rate in patients of younger age compared with older patients. This finding implies that DA turnover in younger-onset patients undergoes a relatively greater alteration and thus likely contributes to a greater imbalance between DA synthesis, storage and release, which could lead to larger swings in synaptic DA levels. It has indeed been suggested on theoretical grounds that such imbalance may contribute to the greater propensity for motor fluctuations. These results provide one possible explanation for the age-dependent occurrence of complications and support the existence of a pre-synaptic contribution to the occurrence of motor complications.

Key Words: dopaminergic system; DA turnover; motor complications; age dependence

Abbreviations: DA = dopamine; EDV = effective DA distribution volume; FD = 18F-fluorodopa; 18F-DA = 18F-fluorodopamine; Ki = FD uptake rate constant; 3OMFD = 3-O-methylfluorodopa; PET = positron emission tomography; ROIs = regions of interest

Received July 28, 2005. Revised January 6, 2006. Accepted January 12, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
R. Nandhagopal, M. J. McKeown, and A. J. Stoessl
Invited Article: Functional imaging in Parkinson disease
Neurology, April 15, 2008; 70(16_Part_2): 1478 - 1488.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
B. Thanvi, N. Lo, and T. Robinson
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
Postgrad. Med. J., June 1, 2007; 83(980): 384 - 388.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.